mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders (Q38046662)

27 August 2017

mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders (English)

1 reference

27 August 2017

autism spectrum disorder

0 references

0 references

1 reference

Lindsay M Oberman

1

1 reference

PubMed ID

23013434

27 August 2017

language of work or name

English

0 references

publication date

26 September 2012

1 reference

Expert Opinion on Investigational Drugs

27 August 2017

1 reference

27 August 2017

21

1 reference

27 August 2017

12

1 reference

27 August 2017

1819-1825

1 reference

The neurology of autism spectrum disorders

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Comorbid psychopathology with autism spectrum disorder in children: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Model of autism: increased ratio of excitation/inhibition in key neural systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Neocortical excitation/inhibition balance in information processing and social dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Syndromic autism: causes and pathogenetic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Increased serum levels of glutamate in adult patients with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Plasma amino acid levels in children with autism and their families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Fragile x syndrome and autism: from disease model to therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

The Autistic Neuron: Troubled Translation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Alterations of GABAergic signaling in autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Serotonin and amino acid content in platelets of autistic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Involvement of reelin and Cajal-Retzius cells in the developmental formation of vertical columnar structures in the cerebral cortex: evidence from the study of mouse presubicular cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Minicolumnar pathology in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Neuronal density and architecture (Gray Level Index) in the brains of autistic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

GABA(B)-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Pathways to drug development for autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: possible implications for the pharmacotherapy of autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Suppression of LTP-like plasticity in human motor cortex by the GABAB receptor agonist baclofen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.729819

10.1517/13543784.2012.729819

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

23013434